Basket Trials (as of June 2022) ENGOT-GYN4/NOGGO/EXPRESSION IX Leading group: NOGGO Clinical Trial Study: Expression IX-Longterm survival with gynecological cancer Planned number of patients: 1000 (100-200 per country) Participating groups: BGOG, A-AGO, MITO, TRSGO, NSGO, SwissGO, CEEGOG, ANZGOG ENGOT-GYN3/AGO/LIO Leading group: AGO Clinical Trial Study: LIO-1: A phase 1b/2, open-label study to evaluate the safety and efficacy of lucitanib in combination with nivolumab in patients with an advanced, metastatic solid tumor Planned number of patients: 161 Participating groups: BGOG, GEICO, MITO, NOGGO ENGOT-GYN2/GINECO/BOUQUET Leading group: GINECO Clinical Trial Study: A multicenter, multi-arm, open-label, genomics-driven phase II study evaluating the clinical benefit of molecularly targeted therapies alone or in combination in patients with progressive locally-advanced or metastatic rare gynecologic tumors after one line of systemic therapy Planned number of patients: 20 patients per cohort Participating groups: AGO, BGOG, CEEGOG, GEICO, MITO, MaNGO, Swiss GO, TRSGO, NCRI ENGOT-GYN1/NCRI/ATARI Leading group: NCRI Clinical Trial Study: ATARI Trial: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss Planned number of patients: 116 Participating groups: GINECO, Princes Margaret Consortium Canada Next ENGOT meeting ENGOT General Assembly March 9-10, 2023 Milan, Italy Directly to: ESGO Annual Congress ESGO‘s Journal latest articles myESGO ESGO Newsletter Get notified on all news and activities right in your mailbox. Sign-up Now! You May Also Like GCA WORKSHOPS Watch the Webcasts Read More CLINICAL TRIALS Latest Published Research Read More FOR PATIENTS Key Insights Read More ESGO MEETING ESGO Congress 2022 Read More